Cargando…

Neoadjuvant anti-PD-1 immunotherapy for recurrent glioblastoma

Detalles Bibliográficos
Autores principales:	Mitchell, Dana, Dey, Mahua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2019
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451720/ https://www.ncbi.nlm.nih.gov/pubmed/32864354 http://dx.doi.org/10.21037/tcr.2019.05.24

Ejemplares similares

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
por: Cloughesy, Timothy F., et al.
Publicado: (2019)

Revisiting anti-angiogenic therapy for recurrent glioblastoma
por: Peters, Katherine B.
Publicado: (2019)

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
por: Zhang, Yaxiong, et al.
Publicado: (2018)

Predictive models for response and survival in patients treated with anti-PD-1 monotherapy or with anti-PD-1 and ipilimumab combination: editorial commentary
por: Rotte, Anand
Publicado: (2023)

Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients
por: Mirjačić Martinović, Katarina, et al.
Publicado: (2023)

Neoadjuvant immunotherapy with resectable non-small cell lung cancer: recent advances and future challenges
por: Ren, Sijia, et al.
Publicado: (2020)

Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy
por: Zuazo, Miren, et al.
Publicado: (2020)

Is Weak Acid Beneficial for Addressing Checkpoint Inhibitor–Triggered Cancer Hyper Progression in Anti-PD1/PD-L1 Immunotherapies?
por: Wan, Yulin, et al.
Publicado: (2020)

Neoantigen personalized vaccine plus anti-PD-1 antibody in cancer patients
por: González-Cao, María, et al.
Publicado: (2022)

Recurrent Glioblastoma: Nuances and Insights
por: Alimohamadi, Maysam, et al.
Publicado: (2021)

Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy
por: Hu, Weixian
Publicado: (2019)

Abscopal effect of stereotactic radiotherapy combined with anti‐PD‐1/PD‐L1 immunotherapy: Mechanisms, clinical efficacy, and issues
por: Zhuang, Hongqing
Publicado: (2020)

Anti-PD1 monotherapy in hepatocellular carcinoma: a step forward or already behind?
por: Catanese, Silvia, et al.
Publicado: (2020)

Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma
por: Garzon-Muvdi, Tomas, et al.
Publicado: (2018)

Sexual dimorphism of the immune system predicts clinical outcomes in glioblastoma immunotherapy: A systematic review and meta-analysis
por: Shireman, Jack M, et al.
Publicado: (2022)

Prospects of the potential strategies to improve the efficacy of anti‐PD‐1/PD‐L1 therapy
por: Yamaguchi, Hirohito, et al.
Publicado: (2022)

Adjuvant therapy in completely resected, EGFR-mutant non-small cell lung cancer: a comparative analysis of treatment efficacy between EGFR-TKI and anti-PD-1/PD-L1 immunotherapy
por: Li, Zichun, et al.
Publicado: (2023)

Quantitative spatial profiling of PD-1/PD-L1 interaction in patients with cancer
por: Hakozaki, Taiki
Publicado: (2023)

Moving beyond the T cell synapse for combination neoadjuvant immunotherapy in head and neck cancer
por: Bell, R. Bryan, et al.
Publicado: (2022)

Neoadjuvant immunotherapy for resectable esophagal squamous cell carcinoma: An ace up the sleeve
por: Zhou, Qing, et al.
Publicado: (2023)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Evolving treatment paradigms in recurrent and metastatic head and neck squamous cell carcinoma: the emergence of immunotherapy
por: Faraji, Farhoud, et al.
Publicado: (2023)

WT1 as an immunotherapy target for thymic epithelial tumors: a novel method to activate anti-tumor immunity
por: Takahashi, Nobuyuki, et al.
Publicado: (2019)

Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy
por: Chatterjee, Samit, et al.
Publicado: (2017)

Why is immunotherapy for glioblastoma “Lag”-ging
por: Mathios, Dimitrios, et al.
Publicado: (2019)

Bevacizumab in recurrent glioblastoma
por: Martinez, Nina L., et al.
Publicado: (2019)

Anti-PD-1 Vasculitis of the central nervous system or radionecrosis?
por: Sun, Roger, et al.
Publicado: (2017)

Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines, anti-PD-1 and poly I:C
por: Zhu, Ping, et al.
Publicado: (2023)

Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer
por: Sweis, Randy F., et al.
Publicado: (2018)

Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer
por: Hashimoto, Ari, et al.
Publicado: (2021)

Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1
por: Lu, Yue, et al.
Publicado: (2021)

The Development of Immunotherapy for the Treatment of Recurrent Glioblastoma
por: Liu, Xudong, et al.
Publicado: (2023)

Anti-PD-1, anti-VEGF, and temozolomide therapy in a patient with recurrent glioblastoma: a case report
por: Chen, Can, et al.
Publicado: (2020)

DNA damage response signaling as a predictive biomarker and synergistic therapeutic target for anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer
por: Zhu, Zhongling, et al.
Publicado: (2018)

Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma
por: Lee, Alexander H., et al.
Publicado: (2021)

Lenvatinib/Pembrolizumab as second line treatment for advanced melanoma patients refractory to programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors
por: Ferrucci, Pier Francesco
Publicado: (2023)

Recurrent Glioblastoma: What Is the Route?
por: Bosio, Alberto, et al.
Publicado: (2023)

Neoadjuvant immunotherapy in early-stage triple negative breast cancer
por: Laouris, Panayiotis, et al.
Publicado: (2023)

Adenovirotherapy delivering cross-hybrid IgGA Fc engineering PD-L1 inhibitors for enhanced cancer immunotherapy
por: Zhao, Guo, et al.
Publicado: (2023)

Optimal radiation dose in the neoadjuvant management of esophageal cancer
por: Buckstein, Michael
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ta1cqesbabhhvv98ln485lalrr